TEL AVIV, Israel, March 5, 2018 /PRNewswire/ --
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the
"Company"), a clinical-stage biopharmaceutical company focused on
the development of the liver targeted SCD1 modulator Aramchol™, a
once-daily, oral therapy for the treatment of nonalcoholic
steatohepatitis, or NASH and other liver diseases, announced today
that it will host a conference call and webcast on Tuesday, March 13th, 2018, to provide
an update on current developments with respect to its clinical
programs for Aramchol™ and to discuss financial results for the
three months and full year ended December
31, 2017.
Conference Call & Webcast:
Tuesday, March
13th @ 8:30am Eastern
Time
Toll-Free: 1-800-289-0438
Toll/International: 1-323-794-2423
Conference
ID: 1228226
Webcast:
http://public.viavid.com/index.php?id=128520
Replays available through March 27,
2018
Toll-Free:
1-844-512-2921
Toll/International: 1-412-317-6671
Replay
PIN:
1228226
About Aramchol™ and Non-alcoholic Steatohepatitis
(NASH)
Aramchol™ (arachidyl amido cholanoic acid) is a novel fatty acid
bile acid conjugate, inducing beneficial modulation of
intra-hepatic lipid metabolism. Aramchol™'s ability to modulate
hepatic lipid metabolism was discovered and validated in animal
models, demonstrating downregulation of the three key pathologies
of NASH: steatosis, inflammation and fibrosis. The effect of
Aramchol™ on fibrosis is mediated by downregulation of steatosis
and directly on human collagen producing cells. Aramchol™ has been
granted Fast Track designation status by the FDA for the treatment
of NASH.
NASH is an emerging world crisis impacting an estimated 3% to 5%
of the U.S. population and an estimated 2% to 4% globally. It is
the fastest growing cause of liver cancer and liver transplant in
the U.S. due to the rise in obesity. NASH is the progressive form
of non-alcoholic fatty liver disease that can lead to
cardiovascular disease, cirrhosis and liver-related mortality.
About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on
the development of Aramchol™, a first in class, novel, once-daily,
oral therapy for the treatment of NASH for variable populations, as
well as other liver associated disorders. Galmed is currently
conducting the ARREST Study, a multicenter, randomized, double
blind, placebo-controlled Phase IIb clinical study designed to
evaluate the efficacy and safety of Aramchol™ in subjects with
NASH, who are overweight or obese, and who are pre-diabetic or
type-II-diabetic. More information about the ARREST Study may be
found on ClinicalTrials.gov identifier: NCT02279524.
View original
content:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-to-report-full-year-and-fourth-quarter-2017-financial-results-and-provide-business-update-on-tuesday-march-13-300607900.html
SOURCE Galmed Pharmaceuticals Ltd.